KMTS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KMTS exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health and financial instability. Despite strong top-line revenue growth of 62.7% and a high current ratio of 7.32, the company suffers from deep negative profit margins (-172.99%) and a complete lack of positive earnings. The disconnect between the 'Strong Buy' analyst consensus and the actual technical trend (0/100) and bearish insider selling suggests a significant valuation bubble or over-optimism regarding future scaling.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
KMTS vs LLY: Head-to-Head Comparison
This page compares Kestra Medical Technologies, Ltd. (KMTS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.